Globalworld globe
United Kingdom
North America
  • facebook
  • linkedin
Medical Developments International
  • Home
  • Products
    • Asthma & COPD
    • Penthrox
    • Medical Devices
    • Veterinary
  • About
    • Distributor Information
    • Careers
    • Associations
  • Investors/Media
    • Financial Reports
    • Board of Directors/Management
    • Corporate Governance
    • Media Centre
    • Diversity Policy
    • Share Trading Policy
  • Healthcare Professionals
  • Contact

News

Penthrox receives regulatory approval in the UAE

Sep 9, 2016Cathy WilsonNews

9 September 2016

ASX ANNOUNCEMENT

Penthrox receives regulatory approval in the UAE

Medical Developments International Limited (ASX: MVP) is delighted to announce that it has received regulatory approval and the Marketing Authorisation (MA) for the sale of Penthrox in the United Arab Emirates (UAE).

The CEO of MVP, Mr. Sharman said: ?Penthrox has been supplied for a number of years into the UAE on a ?Named Patient Basis? and is used in many of the major private and public hospitals as well as the major Ambulance services.

For details relating to the full ASX release, please click on the following link:?Penthrox receives regulatory approval in the UAE

Contact Us

for information on our range of products

Find a distributor

in our global network

Investors

invest in a company with
innovative foresight

News

  • FY21 Half Year Report and Accounts

    26 February 2021 ASX ANNO...

  • MVP Completes $25m Placement

    14 December 2020 ASX ANNO...

  • EU Transition and Trading Update

    3 December 2020 ASX ANNOU...

Healthcare Professional Registration

Login to access healthcare professional resources



Remember Me


Forgot password? | Register

Medical Developments International

Address:
4 Caribbean Drive, Scoresby,
Victoria, 3179
Australia
Phone: +61 3 9547 1888
Email: mdi@medicaldev.com
ABN: 14 106 340 667
For Medical Enquiries:

Phone: 1800 PENTHROX (1800 736 847)
Email: medinf@medicaldev.com

Email Newsletter

Sign up to our newsletter to receive MDI corporate, investor  & media news.